These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7923693)

  • 1. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis.
    Tanaka A; Matsumori A; Wang W; Sasayama S
    Circulation; 1994 Oct; 90(4):2051-5. PubMed ID: 7923693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus.
    Araki M; Kanda T; Imai S; Suzuki T; Murata K; Kobayashi I
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):61-5. PubMed ID: 7564367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice.
    Yamamoto K; Shioi T; Uchiyama K; Miyamoto T; Sasayama S; Matsumori A
    J Am Coll Cardiol; 2003 Dec; 42(11):2000-6. PubMed ID: 14662266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist.
    Ono K; Matsumori A; Shioi T; Furukawa Y; Sasayama S
    Circulation; 1999 Oct; 100(17):1823-9. PubMed ID: 10534471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
    Kito G; Ito K; Shiomi M
    Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
    Matsumori A; Sasayama S
    Eur Heart J; 1995 Dec; 16 Suppl O():140-3. PubMed ID: 8682082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.
    Furukawa Y; Matsumori A; Hirozane T; Sasayama S
    Circulation; 1996 Jan; 93(2):333-9. PubMed ID: 8548907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin.
    Yu F; Chen R; Takahashi T; Sumino H; Morimoto S; Nakahashi T; Iwai K; Matsumoto M; Kanda T
    Int J Cardiol; 2008 Oct; 129(3):414-21. PubMed ID: 18053594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice.
    Baba T; Kanda T; Kobayashi I
    Life Sci; 2000 Jun; 67(5):587-97. PubMed ID: 10993124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
    Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
    Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog.
    Miyazaki M; Shiota N; Sakonjo H; Takai S
    Jpn J Pharmacol; 1999 Apr; 79(4):455-60. PubMed ID: 10361885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury.
    Yoshiyama M; Kim S; Yamagishi H; Omura T; Tani T; Yanagi S; Toda I; Teragaki M; Akioka K; Takeuchi K
    Am Heart J; 1994 Jul; 128(1):1-6. PubMed ID: 8017262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus.
    Yamada T; Matsumori A; Sasayama S
    Circulation; 1994 Feb; 89(2):846-51. PubMed ID: 8313574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
    Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression.
    Saegusa S; Fei Y; Takahashi T; Sumino H; Moriya J; Kawaura K; Yamakawa J; Itoh T; Morimoto S; Nakahashi T; Iwai K; Matsumoto M; Kanda T
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):155-60. PubMed ID: 17484035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.
    Kawamura M; Terashita Z; Okuda H; Imura Y; Shino A; Nakao M; Nishikawa K
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1664-9. PubMed ID: 8371164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
    Kim S; Ohta K; Hamaguchi A; Omura T; Yukimura T; Miura K; Inada Y; Ishimura Y; Chatani F; Iwao H
    J Pharmacol Exp Ther; 1995 Apr; 273(1):509-15. PubMed ID: 7714806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.